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Allopurinol is the most popular commercially available xanthine oxidase inhibitor and it
is widely used for treatment of symptomatic hyperuricaemia, or gout. Although, several
anti-inflammatory actions of allopurinol have been demonstrated in vivo and in vitro, there
have been few studies on the action of allopurinol on T cells. In the current study, we have
assessed the effect of allopurinol on antigen-specific and mitogen-driven activation and
cytokine production in human T cells. Allopurinol markedly decreased the frequency of
IFN-γ and IL-2-producing T cells, either after polyclonal or antigen-specific stimulation with
Herpes Simplex virus 1, Influenza (Flu) virus, tetanus toxoid and Trypanosoma cruzi-derived
antigens. Allopurinol attenuated CD69 upregulation after CD3 and CD28 engagement and
significantly reduced the levels of spontaneous and mitogen-induced intracellular reactive
oxygen species in T cells. The diminished T cell activation and cytokine production in the
presence of allopurinol support a direct action of allopurinol on human T cells, offering
a potential pharmacological tool for the management of cell-mediated inflammatory
diseases.
Keywords: allopurinol, T cells, xanthine oxidase, Th1 cytokines, anti-inflammatory
INTRODUCTION
Allopurinol is the most popular commercially available xanthine
oxidase inhibitor. This molecule and its in vivo active metabolite
oxypurinol act as hypoxanthine analogs that irreversibly inhibit
xanthine oxidase leading to an inhibition of the catalytic reac-
tion that generates uric acid from hypoxanthine and xanthine,
with the concomitant production of superoxide (O−2 ) and hydro-
gen peroxide (H2O2) (Elion, 1988). Since its approval by the
Food andDrugAdministration in 1966, allopurinol has been used
for treatment of symptomatic hyperuricaemia, or gout (Pacher
et al., 2006). However, allopurinol presents a wide range of other
potential therapeutic applications such as chronic kidney disease,
ischemic reperfusion injury, ischemic heart disease, hypertension,
chronic heart failure (Pacher et al., 2006), vascular endothelial
dysfunction (George and Struthers, 2009), lens-induced uveitis
(Augustin et al., 1994, 1996) and chemotherapy of parasitic infec-
tions such as leishmaniasis and Chagas disease (Apt et al., 2005;
Harzallah et al., 2010). It was also demonstrated that allopurinol
reduces rejection in renal transplant recipients when combined
with azathioprine/cyclosporine/prednisolone regimens (Chocair
et al., 1993).
Abbreviations: 7-AAD, 7-aminoactinomycin D; AL, allopurinol; DCF, 2′ 7′-
dichlorofluorescein; DCFH-DA, 2′ 7′-dichlorofluorescin di-acetate; DV, drug vehi-
cle; HSV-1, herpes simplex virus-1; iROS, intracellular reactive oxygen species;
PBMC, peripheral blood mononuclear cells; PMA, Phorbol 12-myristate 13-
acetate; T. cruzi, Trypanosoma cruzi.
Several anti-inflammatory actions of allopurinol have been
demonstrated in vivo and in vitro, probably related with its
dose-dependent free radical scavenging ability (Namazi, 2004).
Allopurinol decreases the production of Tumor Necrosis
Factor-α by human mononuclear cells (Oláh et al., 1994), down-
regulates the expression of Intercellular Adhesion Molecule 1
(ICAM-1 or CD54) and P2X7 purinergic receptor on human
monocytes/macrophages (Mizuno et al., 2004), decreases
antigen-specific B cell responses in Ovalbumin-immunized
BALB/c mice (Kato et al., 2000) and blocks the induction of
Monocyte Chemotactic Factor-1 and Interleukin-6 produc-
tion in rat vascular smooth muscle cells (Lee et al., 2005).
However, the action of allopurinol on T cells is less known.
In this regard, allopurinol has been reported to significantly
suppress phytohaemagglutin-induced lymphocyte blastogenesis
(Kurashige et al., 1985). As allopurinol is a widely prescribed
drug with immunomodulatory action and has been proposed
as a good candidate for treatment of inflammatory-mediated
diseases in which T cells are involved (Grus et al., 2003; Govani
and Higgins, 2010), it would be of interest to clarify any
putative capacity of allopurinol to modulate T cell activation.
Herein, we show that allopurinol diminishes activation as well
as cytokine and intracellular reactive oxygen species produc-
tion by T cells following antigen specific or mitogen-driven
stimulation of human peripheral blood mononuclear cells
(PBMC).
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MATERIALS AND METHODS
SELECTION OF STUDY POPULATION
Healthy adult volunteers (n = 21) aged 27–53 years and asymp-
tomatic chronically Trypanosoma cruzi-infected adult subjects
(n = 7) aged 38–52 years living in urban areas of Buenos Aires,
Argentina, were recruited at the Hospital Interzonal General
de Agudos “Eva Peron” Buenos Aires, Argentina. Subjects with
hypertension, ischemic heart disease, cancer, HIV infection,
syphilis, diabetes, arthritis, or serious allergies were excluded from
the present study. This protocol was approved by the Institutional
Review Board of the Hospital Interzonal General de Agudos
“Eva Peron.” Signed informed consents were obtained from all
individuals before inclusion in the study, and are stored by the
authors.
COLLECTION OF HUMAN PBMC
Blood samples were obtained by venipuncture and PBMC were
isolated by density gradient centrifugation on Ficoll-hypaque
(Amershan, Sweden) and were cryopreserved for later analysis.
DRUGS AND ANTIGENS
Allopurinol was purchased from USP/BP, Italy. Whole viral par-
ticles from Herpes Simplex virus 1 (HSV-1), strain F, were
kindly provided by Dr. Carlos A Pujol (Laboratorio de Virología,
Departamento de Química Biológica, Universidad de Buenos
Aires, Argentina) and obtained as described elsewhere (Matsuhiro
et al., 2005). Briefly, HSV-1 strain F was originally obtained
from the American Type Culture Collection (Rockville, USA) and
propagated in Vero (African green monkey kidney) cells grown in
Eagle’s minimum essential medium (EMEM, Sigma, USA) sup-
plemented with 1.5% calf serum in 150 cm2 cell culture flasks
(BD Falcon, USA). Supernatant from HSV-1-infected Vero cell
cultures was titrated by plaque formation and used as antigenic
stimulation. Supernatant from non-infected Vero cell cultures
did not induce T cell responses in ELISPOT assays with PBMC.
Peptides derived from Influenza (Flu) virus with high bind-
ing affinity for the common class I HLA-supertypes A01, A02,
A03, B27, and B35 were synthesized at the University of Georgia
Molecular Genetics Instrumentation Facility (Athens, USA). A
commercial vaccine (Tetanol Pur, ELEA, Novartis, Germany) was
used as an antigen source for tetanus toxoid. An amastigote lysate
preparation derived from the Brazil strain of Trypanosoma cruzi
(T. cruzi) was obtained as previously described (Laucella et al.,
2004).
DETERMINATION OF ALLOPURINOL CYTOTOXICITY
Three ×106 PBMC were incubated in 24-well plates in com-
plete RPMI 1640 10% fetal calf serum in the presence or absence
of allopurinol in a concentration range from 25 to 300μg/ml
or drug vehicle (10mM NaOH) during 2, 24 or 48 h at 37◦C.
The frequency of total viable and nonviable CD8+, CD4+, and
CD14+ cells were determined by staining with 1μg/ml 7-Amino-
actinomycin D (7-AAD) in combination with anti-human CD8
(APC), anti-human CD4 (PE) and anti-human CD14 (FITC)
antibodies (Becton Dickinson, USA) for 30min at 4◦C. Cells were
then washed, fixed with 2% paraformaldehyde and acquired in a
FacsCalibur flow cytometer (Becton Dickinson, USA). Analysis
was performed with FlowJo software (Tree Star, USA). At least
5 × 105 events were collected per sample.
IFN-γ AND INTERLEUKIN 2 ENZYME-LINKED IMMUNOSORBENT
SPOT (ELISPOT) ASSAYS
The number of antigen-specific Interferon-gamma (IFN-γ)-
secreting or interleukin-2 (IL-2)-secreting T cells for the dif-
ferent stimuli assessed was determined by ex vivo ELISPOT
using commercial kits (ELISPOT Human IFN-γ and IL-2 Sets;
Becton Dickinson, USA), as described by the manufacturer.
Cryopreserved PBMC were seeded in triplicate wells, at a con-
centration of 4 × 105 cells/well, and were stimulated with HSV-1
(at a multiplicity of infection of 10 plaque forming units/cell),
Flu-derived peptide pool (1μg/ml/peptide), tetanus toxoid (1/20
dilution) orT. cruzi lysate (10μg/ml) in the presence of drug vehi-
cle alone (10mM NaOH) or allopurinol (300μg/ml in 10mM
NaOH) for 18–20 h. Stimulation of PBMCwith 20 ng/ml Phorbol
12-myristate 13-acetate (PMA, Sigma, USA) plus 500 ng/ml
Ionomycin (Sigma, USA) in media was used as positive con-
trol of cytokine secretion, while PBMC incubated in media with
the addition of allopurinol or drug vehicle served to determine
the basal levels of spot-forming cells. For set-up of experimen-
tal conditions, 4 × 105 PBMC were stimulated with 100 ng/ml
of anti-CD3 in combination with 100 ng/ml of anti-CD28 anti-
bodies (Becton Dickinson, USA) in the presence of drug vehicle
alone or different allopurinol concentrations for 18–20 h. Spots
were counted and analyzed by Analyzer and ImmunoSpot soft-
ware (version 6.5; CTL, USA). Responses were considered positive
if the number of spot-forming cells in the presence of antigen was
at least twice the number of spots in the presence of media, and
the number of spots in the latter was less than 10 per 4 × 105
cells. The number of specific IFN-γ and IL-2-secreting T cells
was calculated by subtracting the value of the wells containing
media alone from the antigen/mitogen-stimulated spot count.
Only subjects that presented positive antigen-specific responses
were included in these assays.
CD69 SURFACE EXPRESSION
Cryopreserved PBMC were incubated over night at 37◦C in
24-well plates in complete RPMI 1640 10% fetal calf serum at a
density of 106 cells/ml. Cells were then stimulated with 1μg/ml of
anti-CD3 in combination with 1μg/ml of anti-CD28 antibodies
(Becton Dickinson, USA) in the presence of drug vehicle alone or
300μg/ml allopurinol during 5 h. PBMC cultured with complete
RPMI in the presence of drug vehicle alone or 300μg/ml allop-
urinol served as unstimulated control cells. Then, the cells were
washed and stained with anti-human CD4 (PerCP), anti-human
CD8 (APC) and anti-human CD69 (PE) (Becton Dickinson,
USA) for 30min at 4◦C. At least 5 × 105 events were collected per
sample in a FacsCalibur flow cytometer (Becton Dickinson,USA).
Analysis was performed with FlowJo software (Tree Star, USA).
INTRACELLULAR REACTIVE OXYGEN SPECIES (iROS)
DETERMINATION
iROS levels were determined as described previously (Yano
et al., 1998). Briefly, cryopreserved PBMC were thawed and 1 ×
106 PBMC were stained with anti-human CD3 APC (Becton
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Dickinson, USA) in PBS for 15min at room temperature.
Cells were then washed and further incubated with 100 nM 2′
7′-dichlorofluorescin di-acetate (DCFH-DA, Sigma, USA) for
15min at 37◦C and shaking, with or without 300μg/ml allop-
urinol in PBS. In this case, allopurinol was directly dissolved
into PBS to avoid the use of drug vehicle. Thereafter, 100 nM
PMA or PBS alone was added to the culture for additional 1hr
at 37◦C under shaking. Cells were acquired in a FacsCalibur flow
cytometer (Becton Dickinson, USA) and analyzed with FlowJo
software (Tree Star, USA). At least 2 × 105 events were collected
per sample. The intracellular hydrolyzed and oxidized form, 2′
7′-dichlorofluorescein (DCF), was detected at the FL-1 chan-
nel. DCF mean fluorescence intensity represents a measure of
iROS.
STATISTICAL ANALYSIS
The Kruskal-Wallis nonparametric test was used to compare
the percentages of surface markers expression and 7-AAD
incorporation in PBMC treated with different concentrations of
allopurinol or drug vehicle. The Wilcoxon signed rank test was
applied to compare the frequencies and sizes of spot-forming
cells, CD69 expression and iROS production between untreated
and allopurinol-treated PBMC. Differences were considered to be
statistically significant at P < 0.05.
RESULTS
In vitro TREATMENTWITH ALLOPURINOL EXERTS NO
CYTOTOXICITY AND HAS NO INFLUENCE ON CD4, CD8,
AND CD14 EXPRESSION
In order to rule-out any possible cytotoxic effect of allopurinol
on human PBMC, cell viability was evaluated by staining with
7-AAD, a nucleic acid fluorescent dye that penetrates the cell
membrane of nonviable cells and allows the quantification of
dying or dead cells by flow cytometry. Allopurinol did not affect
either cell viability (Figures 1A–D) or the constitutive expres-
sion of CD4, CD8, and CD14, regardless the dose (Figures 1E–G)
in a 48 h assay. Neither significant difference in cell viability or
in the expression of surface markers was recorded after 2 or
24 h-incubation in the presence of allopurinol (data not shown).
ALLOPURINOL DECREASES POLYCLONAL PRODUCTION OF IFN-γ
AND IL-2 BY HUMAN PBMC
We have evaluated the effect of allopurinol on the ability of
human T cells to secrete IFN-γ and IL-2 after stimulation
with different pathogen-specific antigens. Considering that pre-
vious studies have shown that treatment of human PBMC with
allopurinol in a range of 25–100μg/ml impairs several mono-
cyte functions (Mizuno et al., 2004), experimental conditions
for cytokine secretion by the ELISPOT technique were set-up
by stimulation of PBMC with anti CD3/CD28 antibodies in
the presence of 25–300μg/ml allopurinol. Although decreases
in both IFN-γ (Figures 2A–C) and IL-2 (Figures 2E–G) pro-
duction were already observed at 100μg/ml allopurinol, these
decreases became significant with 300μg/ml allopurinol. Thus,
the latter concentration was chosen for further studies. Drug
vehicle alone did not exert any effect on cytokine production
(Figures 2D andH).
In vitro TREATMENTWITH ALLOPURINOL ATTENUATES
ACTIVATION-DRIVEN CD69 EXPRESSION IN HUMAN T CELLS
CD69 is a cell surface molecule upregulated early after T cell
activation (Hara et al., 1986; Cosulich et al., 1987; Risso et al.,
1989). In this study, we also evaluated the effect of allopuri-
nol on early events of human T cell activation by measuring
alterations in CD69 expression. As shown in Figure 3, allop-
urinol attenuates CD69 upregulation on CD4+ (Figure 3A and
top panels Figure 3C) and CD8+ (Figure 3B and bottom panels
Figure 3C) T cells after anti-CD3/CD28 stimulation. The mean
fold increase in CD69 expression after anti-CD3/CD28 stimula-
tion was 38% and 30% lower in the presence of allopurinol for
CD4+ and CD8+ T cells, respectively, compared with drug vehi-
cle alone. Conversely, neither allopurinol nor the drug vehicle
altered the expression of CD69 on unstimulated T cells after the 5
h-incubation period (Figures 3A–C).
In vitro TREATMENTWITH ALLOPURINOL REDUCES iROS
PRODUCTION IN HUMAN T CELLS
T cells increase the production of ROS early after activation and
their effector function is strongly regulated by ROS, through
distinct T cell receptor (TCR) pathways (Devadas et al., 2002;
Williams and Kwon, 2004; Yan and Banerjee, 2010). Taking into
account that allopurinol is a potent scavenger of ROS (Moorhouse
et al., 1987) and presents antioxidant activities in vivo (Augustin
et al., 1994), we hypothesized that allopurinol action on T cell
activation could be explained by its scavenging action during early
activation events of T cells. We therefore studied the allopurinol
action on iROS production in human T cells by measuring DCF
mean fluorescence intensity in response to PMA, a known stim-
ulus for iROS production in human T cells (Yano et al., 1998).
Allopurinol significantly reduced either the levels of spontaneous
(Figures 4A and B) or PMA-induced (Figures 4A and C) iROS in
total T cells.
ALLOPURINOL DECREASES ANTIGEN-SPECIFIC IFN-γ AND
IL-2-PRODUCING T CELL RESPONSES IN HUMAN PBMC
The effect of allopurinol on antigen-specific cytokine production
by T cells was also evaluated. To achieve this aim, T cell responses
specific for pathogen-derived antigens representative of different
infection models, including a chronic viral infection (HSV-1),
a solved viral infection (Flu) and a parasitic chronic infection
(T. cruzi) were measured ex vivo by IFN- γ and IL-2 ELISPOT
assays. T cell responses specific for Tetanus toxoid were also ana-
lyzed in a group of vaccinated subjects. Allopurinol markedly
decreased the frequency of IFN-γ-producing T cells indepen-
dently of the antigen used as stimuli, including full viral particles
from HSV-1, a Flu-derived peptide pool with high binding affin-
ity for common class I HLA-supertypes, tetanus toxoid and a
T. cruzi lysate preparation (Figures 5A–D). Likewise, IL-2 pro-
duction was also diminished in the presence of allopurinol upon
stimulation with T. cruzi antigens (Figure 5E). The mean spot
size of IFN-γ was significantly decreased in the presence of
allopurinol, indicating not only a reduction in the frequency of
IFN-γ-producing T cells, but also in cytokine production at a
single cell level (Figures 6A and B). As seen after polyclonal stim-
ulation, drug vehicle alone did not have any effect on cytokine
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FIGURE 1 | In vitro treatment with allopurinol exerts no cytotoxicity and
has no influence on CD4, CD8, and CD14 constitutive expression. PBMC
from healthy donors were isolated by density gradient centrifugation on
Ficoll-hypaque. PBMC were incubated in the presence or absence of
allopurinol (25–300μg/ml) or drug vehicle (10mM NaOH) during 48h and
analyzed by four color flow cytometry. The frequency of total non-viable and
viable CD14+, CD4+, and CD8+ cells were determined by staining with
1μg/ml 7-aminoactinomycin D (7-AAD) in combination with CD14 (FITC), CD4
(PE), and CD8 (APC) antibodies. (A–D) Representative gate selection and
analysis for monocytes and T cells. Monocytes (R1) and lymphocytes (R2)
were gated by forward and side light scatter (A), including an area generally
enriched in death cells (R3). CD14+, CD4+, or CD8+ cells were selected, and
from these populations 7-AAD histograms were made to determine the
percentages of 7-AAD+ (on the right) and 7-AAD− (on the left) cells on total
CD14+ (B), CD4+ (C) or CD8+ (D) T cells. Mean percentages ± SEM of
CD4+7-AAD+ (E), CD8+7-AAD+ (F) or CD14+7-AAD+ (G), (left Y axis, black
bars) and CD4+7-AAD− (E), CD8+7-AAD− (F) or CD14+7-AAD− (G), (right Y
axis, white bars) from 5 samples assessed. P > 0.05 among different
allopurinol concentrations, drug vehicle, and media alone, as determined by
Kruskal–Wallis test. AL, allopurinol.
production after antigen-specific stimulation (Figures 5A–E and
Figures 6A and B).
DISCUSSION
Xanthine Oxidase inhibitors have emerged as therapeutic tools
for inflammatory-mediated diseases, including those in which T
cells are involved (Grus et al., 2003; Pacher et al., 2006; Govani
and Higgins, 2010; Ng et al., 2011; Sliem and Nasr, 2011). In
the present study, the effect of allopurinol on late (i.e., cytokine
production) as well as on early (i.e., CD69 expression and iROS
production) events of human T cell activation was investigated.
We show, for the first time, that allopurinol decreases class I and
class II-restricted antigen-specific and polyclonal IFN-γ and IL-2
production, in addition to the expression of activation markers by
human T cells.
Antigen-specific activation of T cells requires recognition of
peptide-MHC complexes by the TCR on antigen presenting cells,
costimulation and the expression of adhesion molecules. The
recognition of antigen by the TCR initiates transcriptional acti-
vation of particular genes that mediate T cell responses. We
found that allopurinol decreased IFN-γ production by T cells
specific for different pathogens probably due to a direct effect
of the drug on T cells as well as on antigen-presenting cells.
This view is supported by other findings showing that allop-
urinol downregulates the expression of ICAM-1 on monocytes
(Mizuno et al., 2004) and modulates protein kinase C activity
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FIGURE 2 | Effect of different concentrations of allopurinol on polyclonal
activation-driven IFN-γ and IL-2 production by human T cells. PBMC from
healthy donors were stimulated with anti-CD3 (100ng/ml) plus anti-CD28
(100ng/ml) antibodies, or remained with media alone, in the presence of
different concentrations of allopurinol (+ AL) or drug vehicle (+ DV), for
18–20h and the number of IFN-γ-secreting (A–D) or IL-2-secreting (E–G)
T cells were determined by ex vivo ELISPOT assays. (D and H) The samples
were cultured in media with the addition of AL or DV. Each line represents an
individual subject. Panels A–C and E–G show the net number of spot-forming
cells (spot-forming cells in media were subtracted). Dotted lines represent
the threshold for positive IFN-γ or IL-2 ELISPOT responses, as defined in
Materials and Methods. Comparisons between T cell responses in the
absence or presence of allopurinol upon stimulation were performed by
Wilcoxon signed rank test.
(Kang et al., 2006), one of the main enzymes involved in bio-
chemical pathways inducing T cell responses. IFN-γ secretion
was also reduced in the presence of allopurinol after polyclonal
stimulation of T cells with anti-CD3/CD28 that mimics signals
generated by the TCR complex, bypassing the need for T cell-
antigen presenting cell interaction, supporting that allopurinol
might exert a direct action on T cells. Moreover, we showed
that IL-2 production, a cytokine that drives T cell activation, is
reduced in the presence of allopurinol. The lower amounts of
antigen-specific cytokine production, as evidenced by the smaller
spot size and the attenuation of CD69 upregulation upon acti-
vation with CD3/CD28, further support the specific effect of
allopurinol on T cell activation.
Diverse evidences have shown that the redox state can influ-
ence T cell function in vitro and in vivo (Griffiths et al., 2011).
Cross-linking of the TCR and the co-stimulatory molecule CD28
in human T cells results in enhanced iROS production that is
needed for NF-κB and IL-2 expression (Los et al., 1995) and
is consistent with an important role for ROS in the imme-
diate early events during activation (Yan and Banerjee, 2010).
Lipid metabolism, mitochondria, and/or NADPH oxidases have
been claimed to be the source of iROS during T cell activa-
tion (Williams and Kwon, 2004). Although xanthine oxidase
also mediates ROS generation, this enzyme is not expressed
by human immune cells (Dröge, 2002). Xanthine oxidase is
distributed in the liver, gut, lung, kidney, heart, and brain,
accounting for only a minor proportion of total ROS production
under normal conditions (Dröge, 2002). Thus, the modulation
of T cell function observed herein would be accounted for the
ROS scavenging action of allopurinol but not for an inhibition
in ROS production mediated by the xanthine oxidase enzyme.
Thus, allopurinol would deprive T cells from iROS which are
required during the early activation of the NF-kB complex (Los
et al., 1995) and PKC (Kang et al., 2006), thus promoting a
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FIGURE 3 | Allopurinol attenuates activation-driven CD69 upregulation in
CD4+ and CD8+ T cells. PBMCwere incubated for 5 h with media or with
anti-CD3 (1μg/ml) plus anti-CD28 (1μg/ml) antibodies, in the presence of
allopurinol (+ AL, 300μg/ml) or drug vehicle alone (+ DV). Cells were then
stained with anti-CD4 (PerCP), anti-CD8 (APC) and anti-CD69 (PE) and analyzed
with four color flow cytometry. Lymphocyteswere gated by forward and side
light scatter. From this population single color CD4 or CD8 staining histogram
was made, and the expression of CD69 was analyzed. Each line shows the
mean fluorescence intensity (MFI) of CD69 expression on CD4+ (A) or CD8+
(B) T cells before and following stimulation with anti-CD3/CD28 antibodies, in
the presence of drug vehicle (+ DV) or allopurinol (+ AL), for each subject
evaluated. Comparisons between the differences in net CD69
expression (subtracting CD69MFI in media) with and without allopurinol were
performed byWilcoxon signed rank test. Representative histogram plots
of CD69 expression on CD4+ (C, top panels) and CD8+ (C, bottom panels)
T cells with the indicated treatment. The numbers over the bars indicate the
percentages of CD69+ cells and the numbers in the top right corner indicate
theMFI of CD69 expression on CD4+ (top) and CD8+ (bottom) T cells.
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FIGURE 4 | Allopurinol attenuates spontaneous and mitogen-activated
iROS production in human T cells. PBMC were stained with anti-CD3 PE
and incubated at 37◦C for 1 h with DCFH-DA and PBS alone or with PMA
(100nM) in the presence (+ AL, 300μg/ml) or absence of allopurinol. The
oxidized form, DCF represents a measure of iROS. Lymphocytes were
gated by forward and side light scatter. From this population single color
CD3 staining histogram was made, and the expression of DCF in the gated
population was analyzed. (A) Representative iROS expression on CD3+ T
cells in the absence (upper panel) or presence (bottom panel) of allopurinol.
(B) Cumulative data of spontaneous iROS production from 7 subjects. Each
line represents spontaneous iROS levels for each patient in the absence
(PBS) or in the presence (AL) of allopurinol. (C) Cumulative data of induced
iROS production. Each line show iROS release for each subject prior and
following stimulation with PMA in the presence (+ AL) or absence of
allopurinol. Comparisons were performed by Wilcoxon signed rank test.
MFI: mean fluorescence intensity.
hyporesponsive state of T cells. In agreement with this notion,
allopurinol has been recently shown to reduce NF-κB pathway
activation, pro-inflammatory cytokines production, and oxida-
tive stress in different in vivo models of inflammation (Correa-
Costa et al., 2011; Aldaba-Muruato et al., 2012; Demirel et al.,
2012).
Both T cells and dendritic cells elevate the intracellular oxi-
dation status upon antigen-specific interaction, and bidirectional
dendritic cell-T cell communication can be blocked by interfering
with redox regulation pathways (Matsue et al., 2003). Moreover,
alteration in redox status of T cells and dendritic cells has been
recently proposed as a putative mechanism of regulatory T cells
action (Yan et al., 2010). Although, we cannot rule out the
possibility that the effect of allopurinol on antigen-specific T cell
responses is due to, at least partially, an impairment in antigen
presentation by the action of allopurinol on antigen-presenting
cells, the reduction of iROS production by PMA-stimulated T
cells in the presence of allopurinol for short periods of time fur-
ther supports the idea of a direct action of allopurinol on T cell
activation. Future studies regarding the effect of allopurinol on
the expression of costimulatory molecules, as well as studies at
the transcriptional level on T cells, will help us to further clarify
these ideas.
CD4+ IFN-γ-producing Th1 cells have long been associated
with the pathogenesis of many organ-specific autoimmune dis-
eases (Dardalhon et al., 2008). Herein, we report that these
responses might be inhibited by allopurinol, in vitro. A beneficial
effect of allopurinol on cell-mediated diseases is also supported
by an improvement of the response to thiopurine treatment by
the addition of allopurinol in individuals with inflammatory
bowel disease, a Th1-polarized disease (Gardiner et al., 2011;
Smith et al., 2012). Inflammation has also been pointed out as
a potential target for therapy of chronic heart failure (Celis et al.,
2008), that has been strongly correlated with T cell activation and
altered Th1/Th2 balance (Cheng et al., 2009). iROS production by
phagocytic leukocytes is also increased in heart failure patients
(Castro et al., 2003) and it is a major cause of endothelial dys-
function as iROS can act both, as triggers or amplifiers of the
inflammatory response (Deschamps and Spinale, 2006; Castro
et al., 2008). Several studies have demonstrated that treatment
with xanthine oxidase inhibitors of patients suffering from heart
failure resulted in reduced oxidative stress and improved endothe-
lial function (Landmesser et al., 2002; Castro et al., 2005; Hare
et al., 2008). Our results showed that allopurinol decreases iROS
production by T cells which might have important therapeutic
implications since down-regulation of inflammatory T cells is the
treatment of choice for many inflammatory diseases. In agree-
ment with this notion, the use of a different immunomodulating
agent, Pentoxifylline, improved the clinical status of patients with
idiopathic-dilated and ischemic cardiomyopathy (Barnett and
Touchon, 1990; Skudicky et al., 2000; Sliwa et al., 2002, 2004).
Allopurinol is rapidly absorbed in vivo, reaching peak plasma
concentrations within 30–60min, following oral administration
(Pea, 2005). Allopurinol has relatively short half-life in plasma (2–
3 h) because it is rapidlymetabolized in vivo and converted almost
completely into to the oxidized metabolite, oxypurinol, which has
the same therapeutic pattern but a much longer elimination half-
life (14–30 h) than the parent compound (Pea, 2005). Allopurinol
is negligibly bound to plasma proteins, and gets spread to dif-
ferent tissues, including vascular tissue, liver, intestine, and heart
(Murrell and Rapeport, 1986). Therefore, the maximum pos-
sible concentration of allopurinol in vivo is hard to estimate,
making it difficult to predict the in vivo physiological relevance
of drug concentrations applied, in vitro, in the present study.
Moreover, it has been demonstrated that allopurinol can be dif-
ferentially metabolized in vitro and in vivo (Kramer and Feldman,
1977).
Determination of plasma concentrations of oxypurinol highly
differs depending on the population studied, the dose and
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FIGURE 5 | Allopurinol attenuates antigen-specific activation-driven IFN-γ
and IL-2 production by human T cells. PBMC from healthy donors were
stimulatedwith full viral particles fromHSV-1 (A), a Flu-derivedpeptidepool (B),
tetanus toxoid (C), or cultured in the absence of antigen stimulation (media), in
the presence of allopurinol (+ AL, 300μg/ml) or drug vehicle alone (+ DV) for
18–20h, and the number of IFN-γ-secreting or IL-2-secreting (E) T cells were
determined by ex vivo ELISPOT assays. PBMC from a group of chronically
T. cruzi-infected subjects were stimulated with a T. cruzi-derived amastigote
lysate (D and E). Each line represents an individual subject. Dotted lines
represent the threshold for positive T cell responses, as defined inMaterials and
Methods. Comparisons between T cell responses in the absence or presence
of allopurinol upon stimulation were performed byWilcoxon signed rank test.
the route of administration, the length of treatment and the
time-points after drug intake chosen for measurements (Rodnan
et al., 1975; Breithaupt and Tittel, 1982; Berlinger et al., 1985;
Murrell and Rapeport, 1986; Emmerson et al., 1987; Day et al.,
1988a,b; Graham et al., 1996; Turnheim et al., 1999; Guerra
et al., 2001; Kaya et al., 2006; Panomvana et al., 2008; Stocker
et al., 2008; Van Dijk et al., 2008; Torrance et al., 2009; Stamp
et al., 2011). For instance, Van Dijk et al. demonstrated that
allopurinol reaches a mean maximal plasma concentration of
41.90μg/ml within minutes after a dose of 15mg/kg body
weight administered i.v. in pregnant sows (Van Dijk et al.,
2008). In a survey studying 50 adult patients receiving vari-
able daily doses of allopurinol, with 83% of the patients taking
300mg/day, during 6 ± 7.5 years on average, a wide range of
plasma oxypurinol concentration (i.e., from 2.8 to 55.8μg/ml)
was observed (Day et al., 1988b). Differences in the levels of
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FIGURE 6 | Allopurinol decreases IFN-γ secretion at a single cell level.
IFN-γ ELISPOT assays were performed by stimulation, or not (media), of
PBMC from healthy donors with full viral particles from HSV-1 (A), or PBMC
from a group of chronically T. cruzi-infected subjects with a T. cruzi-derived
amastigote lysate (B), in the presence of allopurinol (+ AL, 300μg/ml) or
drug vehicle (+ DV), for 18–20h. Mean spot sizes represent an estimate of
IFN-γ production per cell. Each line represents an individual subject.
Comparisons between T cell responses in the absence or presence of
allopurinol upon stimulation were performed by Wilcoxon signed rank test.
serum oxypurinol from patient to patient taking the same dose
of allopurinol may result from differences in absorption, rate
of metabolism, xanthine oxidase levels, the amount of drug
bound to xanthine oxidase in the tissues and/or renal func-
tion. Even diet and exercise can significantly alter the phar-
macokinetics of oxypurinol (Berlinger et al., 1985; Kaya et al.,
2006).
In the present work, we observed that a single dose of
100μg/ml allopurinol decreased T cell production of cytokines
within hours after in vitro culture, but reaching a statistical
significant reduction upon treatment with 300μg/ml of allop-
urinol. As oxypurinol accumulates and reaches a steady-state
level during long-term administration (Murrell and Rapeport,
1986), the effect of allopurinol observed within hours after
in vitro culture is probably only comparable to the effect
observed in subjects receiving long-term treatment with allop-
urinol. In this regard, allopurinol is generally well toler-
ated, allowing long-term treatments and administration of
high doses (Momeni and Aminjavaheri, 1995; Momeni et al.,
2002).
Allopurinol, administered at 600mg/day during 3 months,
constitutes a second line drug for the treatment of chronic Chagas
disease, caused by Trypanosoma cruzi infection. Allopurinol was
also shown to be safe and effective in the treatment of Chagas
disease reactivation after heart transplantation (Almeida et al.,
1996; Bestetti and Theodoropoulos, 2009). In a recent pilot
study of a sequential combined treatment with allopurinol and
benznidazole in the chronic phase of Trypanosoma cruzi infec-
tion (Pérez-Mazliah et al., 2012), we have observed that the
frequency of peripheral naïve CD4+ and CD8+ T cells, that are
generally diminished in this phase of the infection (Albareda
et al., 2006, 2009), is improved along with a decrease in the
frequency of peripheral CD4+ and CD8+ T cells expressing
the activation marker HLA-DR after completion of allopuri-
nol administration. These changes were sustained following
the consecutive treatment with benznidazole, supporting the
immunomodulating activity of allopurinol, in vivo, on human
T cells.
Allopurinol hypersensitivity syndromes, like the Stevens-
Johnson syndrome, is an infrequent but life-threatening adverse
effect that affects about 0.4% patients receiving allopurinol ther-
apy (Arellano and Sacristán, 1993; Pluim et al., 1998) and whose
mechanisms remain unclear. Three potential factors involved
in allopurinol hypersensitivity syndromes are the genetic back-
ground, dose accumulation, and immunological responses to the
drug. However, a relationship between the appearance of allop-
urinol hypersensitivity syndromes and the use of high doses has
not been demonstrated (George et al., 2006). Risk factors for
development of allopurinol hypersensitivity syndromes include
aging, renal impairment, diuretic use, and some ethnics groups
(Chinese descent) (Lee et al., 2008). In the same pilot study
mentioned above (Pérez-Mazliah et al., 2012), the use of allop-
urinol in doses of 600mg/day for 90 consecutive days was very
well tolerated and we did not observe any case of severe adverse
reaction. This observation is in agreement with previous stud-
ies (Gallerano et al., 1990; Momeni and Aminjavaheri, 1995; Apt
et al., 1998; Momeni et al., 2002; Apt et al., 2003, 2005), in which
doses even higher than 1 g/day of allopurinol during months
were administered without registering high incidence of adverse
effects.
The immunomodulatory action of allopurinol described in the
present work in combination with previous observations could
raise the idea that allopurinol would favor the occurrence of
opportunistic infections.We have not observed a higher incidence
of opportunistic infections in chronically Trypanosoma cruzi-
infected patients under treatment with doses of 600mg per day
of allopurinol during 3 months (Pérez-Mazliah et al., 2012). This
is again in accordance with previous observations, even in long-
term and high dose treatments with allopurinol (Gallerano et al.,
1990; Momeni and Aminjavaheri, 1995; Apt et al., 1998, 2003,
2005; Momeni et al., 2002). Thus, the immunomodulatory effect
of allopurinol does not seem to generate the level of immunosup-
pression required to favor opportunistic infections in vivo, at least
in the context of the studies cited herein.
Nonetheless, due to its low frequent but potentially severe
side effects as well as its immunomodulatory action, it is highly
recommended a close follow-up of patients receiving allopuri-
nol throughout the entire duration of the treatment. Particular
attention should be paid to those populations at high risk of
developing side effects and those presenting alterations in nor-
mal immune system function. In summary, this study raise
evidence in line with an immunomodulatory action of allop-
urinol on human T cells, offering a potential pharmacolog-
ical tool for the management of cell-mediated inflammatory
diseases.
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